Craft

Imcyse

Total Funding

$46.6 M

Revenue

€453.5 K

FY, 2021

Imcyse Summary

Company Summary

Overview
Imcyse is a biopharmaceutical company that develops immunotherapies for the treatment and prevention of severe chronic diseases. It offers Imotopes, a platform that blocks the immune responses that cause immune-mediated diseases. Its therapeutic area includes diabetes, neuromyelitis optica, rheumatoid arthritis, celiac disease, etc.
Type
Private
Status
Active
Founded
2010
HQ
Liège, BE | view all locations
Website
https://www.imcyse.com
Cybersecurity rating
Sectors

Key People

  • Denis Bedoret

    Denis Bedoret, Chief Executive Officer, Director

  • Thomas Taapken

    Thomas Taapken, Chairman of the Board

  • Christina Franssen

    Christina Franssen, Director

    • Anneleen Boyden

      Anneleen Boyden, Director, PMO

      LocationsView all

      2 locations detected

      • Liège, Région Wallonne HQ

        Belgium

        Avenue Pré-Aily 14

      • Liège, Wallonia

        Belgium

        Avenue de l'Hôpital, 1

      Imcyse Financials

      Summary Financials

      Revenue (FY, 2021)
      €453.5K
      Gross profit (FY, 2021)
      (€11.5M)
      Net income (FY, 2021)
      (€18.6M)
      Cash (FY, 2021)
      €18.1M
      EBIT (FY, 2021)
      (€25.7M)

      Footer menu